Poor tolerability of GLP-1 weight problems medicine leads many sufferers to cease taking them, leading to gaining again the burden that was misplaced. Some drug firms try to develop different approaches that might function upkeep therapies following preliminary remedy with GLP-1 injections, and Response Prescribed drugs now has encouraging mid-stage medical information constructing the case for its capsule.
The Response drug, RDX-002, is an oral small molecule designed to inhibit a goal referred to as intestinal microsomal triglyceride switch protein (iMTP). The Falls Church, Virginia-based biotech says this strategy reduces the uptake of triglycerides (fat) and ldl cholesterol by the physique. Consequently, the physique takes in fewer energy.
Response evaluated RDX-002, taken as a twice-daily capsule, in a Part 2 check that enrolled 68 members who had stopped or had been keen to discontinue the Novo Nordisk GLP-1 drug Wegovy or the Eli Lilly GLP-1 and GIP receptor agonist Zepbound. The primary aim was to measure the change in triglyceride ranges, in comparison with placebo, after 12 weeks. Secondary objectives embody measuring the change in physique weight and levels of cholesterol.
In line with outcomes launched Wednesday, Response’s drug let to statistically vital reductions in fats ranges within the blood after consuming. Moreover, outcomes at 12 weeks confirmed these reductions had been additionally related to discount in weight regain in comparison with a placebo. The startup stated RDX-002 was usually well-tolerated, characterizing antagonistic occasions as principally mild-to-moderate gastrointestinal results. No severe antagonistic occasions had been reported. The corporate stated full Part 2 information can be offered at an upcoming scientific assembly.
RDX-002 was found and initially developed by Floor Logix, a biotech that was acquired by Kadmon Prescribed drugs. In 2021, Sanofi paid $1.9 billion to accumulate Kadmon, a deal centered primarily on Rezurock, a ROCK2 inhibitor that reached the market as a remedy for continual graft-versus-host illness. Response licensed international rights to RDX-002 from Sanofi. In line with Response’s web site, firm co-founder and Chief Scientific Officer Paul Sweetnam led the invention of RDX-002 at Floor Logix. Response introduced an $8 million Collection A financing in 2022.
The lead indication for RDX-002 is addressing weight achieve from antipsychotics, a standard aspect impact of those medicines. A separate Part 2 program is ongoing on this indication. However serving to sufferers preserve weight reduction following GLP-1 remedy opens up one other alternative for the biotech.
“By concentrating on key pathways concerned in metabolic regulation, we intention to supply a sturdy, well-tolerated answer that helps long-term weight administration and cardiometabolic well being,” Response CEO Eric Keller stated in a ready assertion. “We stay dedicated to advancing the event of RDX-002 in our lead indication — antipsychotic-induced weight achieve (AIWG) — concentrating on a extremely metabolically weak inhabitants, in addition to exploring its potential in different areas with vital unmet metabolic want.”
Picture: Peter Dazeley, Getty Photos
